Charles Schwab’s Enzo Biochem, Inc. ENZ Stock Holding History

Charles Schwab’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,471	Closed	-$15.1K	–	3524
2024 Q3	$15.1K	Hold	13,471	–	–	﹤0.01%	3495
2024 Q2	$14.7K	Hold	13,471	–	–	﹤0.01%	3601
2024 Q1	$17.1K	Hold	13,471	–	–	﹤0.01%	3437
2023 Q4	$18.7K	Hold	13,471	–	–	﹤0.01%	3488
2023 Q3	$18.9K	Hold	13,471	–	–	﹤0.01%	3518
2023 Q2	$24.8K	Hold	13,471	–	–	﹤0.01%	3533
2023 Q1	$32.7K	Hold	13,471	–	–	﹤0.01%	3435
2022 Q4	$19.3K	Hold	13,471	–	–	﹤0.01%	3506
2022 Q3	$31K	Hold	13,471	–	–	﹤0.01%	3430
2022 Q2	$28K	Hold	13,471	–	–	﹤0.01%	3488
2022 Q1	$40K	Hold	13,471	–	–	﹤0.01%	3554
2021 Q4	$44K	Hold	13,471	–	–	﹤0.01%	3525
2021 Q3	$48K	Hold	13,471	–	–	﹤0.01%	3458
2021 Q2	$43K	Sell	13,471 -92,538	-87%	-$291K	﹤0.01%	3391
2021 Q1	$365K	Hold	106,009	–	–	﹤0.01%	3186
2020 Q4	$268K	Hold	106,009	–	–	﹤0.01%	3203
2020 Q3	$224K	Sell	106,009 -157,813	-60%	-$375K	﹤0.01%	3146
2020 Q2	$591K	Buy	263,822 +15,756	+6%	+$40.5K	﹤0.01%	2771
2020 Q1	$628K	Buy	248,066 +3,463	+1%	+$8.51K	﹤0.01%	2639
2019 Q4	$644K	Buy	244,603 +2,679	+1%	+$8K	﹤0.01%	2729
2019 Q3	$871K	Sell	241,924 -12,407	-5%	-$43.9K	﹤0.01%	2612
2019 Q2	$858K	Buy	254,331 +22,156	+10%	+$78.1K	﹤0.01%	2626
2019 Q1	$634K	Sell	232,175 -998	-0.4%	-$3.27K	﹤0.01%	2676
2018 Q4	$649K	Sell	233,173 -3,188	-1%	-$10.4K	﹤0.01%	2672
2018 Q3	$974K	Buy	236,361 +14,471	+7%	+$65.7K	﹤0.01%	2637
2018 Q2	$1.15M	Buy	221,890 +7,023	+3%	+$42.8K	﹤0.01%	2548
2018 Q1	$1.18M	Buy	214,867 +36,971	+21%	+$260K	﹤0.01%	2476
2017 Q4	$1.45M	Sell	177,896 -22,554	-11%	-$215K	﹤0.01%	2411
2017 Q3	$2.1M	Buy	200,450 +75,169	+60%	+$834K	﹤0.01%	2271
2017 Q2	$1.38M	Buy	125,281 +20,200	+19%	+$188K	﹤0.01%	2346
2017 Q1	$880K	Hold	105,081	–	–	﹤0.01%	2463
2016 Q4	$730K	Hold	105,081	–	–	﹤0.01%	2530
2016 Q3	$535K	Hold	105,081	–	–	﹤0.01%	2590
2016 Q2	$628K	Buy	105,081 +61,100	+139%	+$339K	﹤0.01%	2513
2016 Q1	$201K	Hold	43,981	–	–	﹤0.01%	2900
2015 Q4	$198K	Hold	43,981	–	–	﹤0.01%	2963
2015 Q3	$140K	Hold	43,981	–	–	﹤0.01%	3005
2015 Q2	$134K	Sell	43,981 -50,100	-53%	-$141K	﹤0.01%	3032
2015 Q1	$278K	Sell	94,081 -8,637	-8%	-$28.3K	﹤0.01%	2866
2014 Q4	$457K	Sell	102,718 -33,673	-25%	-$161K	﹤0.01%	2655
2014 Q3	$703K	Hold	136,391	–	–	﹤0.01%	2463
2014 Q2	$717K	Buy	136,391 +28,050	+26%	+$121K	﹤0.01%	2488
2014 Q1	$451K	Buy	108,341 +34,700	+47%	+$119K	﹤0.01%	2626
2013 Q4	$216K	Hold	73,641	–	–	﹤0.01%	2936
2013 Q3	$185K	Sell	73,641 -5,140	-7%	-$12.2K	﹤0.01%	2945
2013 Q2	$168K	Buy	+78,781	New	+$174K	﹤0.01%	2966

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab's ENZ Position: Q4 2024 in Review

Charles Schwab sold out of Enzo Biochem, Inc. (ENZ) in Q4 2024, closing a stake of 13,471 shares — an estimated $15.1K sold.

Charles Schwab first reported a position in ENZ in Q2 2013 and held it in 46 quarters. The position peaked at $2.1M in Q3 2017. 45 funds tracked by Wall St. Rank hold ENZ as of Q4 2024.

Charles Schwab reported no remaining Enzo Biochem, Inc. position as of Q4 2024 after selling out during the quarter.
Charles Schwab sold 13,471 Enzo Biochem, Inc. shares in Q4 2024, an estimated $15.1K.
Charles Schwab first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 46 quarters.
Charles Schwab's Enzo Biochem, Inc. position peaked at $2.1M in Q3 2017.
45 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.